Phase 2 study to assess safety and efficacy of OBE022 to delay birth after oral administration in pregnant women
Phase of Trial: Phase II
Latest Information Update: 18 May 2017
At a glance
- Drugs OBE 022 (Primary)
- Indications Preterm labour
- Focus Therapeutic Use
- 18 May 2017 ObsEva expects to initiate this trial in 2H 2017, according to a company media release.
- 17 Jan 2017 New trial record
- 13 Jan 2017 According to an ObsEva media release, company plans to initiate this study in 2017.